STAT Plus: Worst Biopharma CEO of 2024? It’s no contest
Adam’s Take
Insights and opinions from senior biotech writer Adam Feuerstein.
Recent topics include Apellis Pharmaceuticals, Moonlake Immunotherapeutics, PDS Biotech, Rubius Therapeutics, Amylyx Pharmaceuticals and Anavex Life Sciences.
Latest
STAT Plus: Who stood out as Best Biopharma CEO of 2024?
STAT Plus: Arcellx won the battle of BCMA CAR-T therapies
STAT Plus: Why Stoke Therapeutics’ Dravet syndrome drug is worth watching
STAT Plus: Why Applied Therapeutics has a credibility problem
STAT Plus: Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
STAT Plus: The state of biotech M&A 2024
STAT Plus: Neurogene and the race to the bottom of gene therapy
All Coverage
advertisement
